Researchers report a persistent deficiency in truly new therapeutics for neglected diseases, despite nominal progress and an acceleration in research and development (R&D) efforts. This continued “fatal imbalance” in medical R&D points to the urgent need to develop and deliver groundbreaking new treatments for the world’s poorest and most neglected patients.